Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
31 studies found for:    Pharmacyclics | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: ibrutinib;   Drug: Placebo;   Drug: Prednisone
2 Not yet recruiting Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Condition: Mantle-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax;   Drug: Placebo Oral tablet to match Venetoclax
3 Recruiting Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Bortezomib;   Drug: Dexamethasone
4 Recruiting A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Conditions: Renal Cell Carcinoma (RCC);   Urothelial Carcinoma;   Gastric Adenocarcinoma;   Colorectal Adenocarcinoma (CRC)
Interventions: Drug: ibrutinib;   Drug: everolimus;   Drug: docetaxel;   Drug: paclitaxel;   Drug: cetuximab
5 Recruiting Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
6 Recruiting Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Conditions: Leukemia, Chronic Lymphocytic;   Lymphoma, Small Lymphocytic
Interventions: Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: venetoclax
7 Recruiting Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Condition: Treatment Naive Follicular Lymphoma
Interventions: Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
8 Recruiting informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention:
9 Recruiting Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Placebo
10 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Dexamethasone
11 Recruiting Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma
Condition: Gastrooesophageal Cancer
Intervention: Drug: ibrutinib
12 Recruiting Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma
Condition: Indolent Non-Hodgkin Lymphoma
Interventions: Drug: Ibrutinib;   Drug: GA 101
13 Not yet recruiting Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
Condition: Richter Syndrome
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib;   Other: CHOP
14 Recruiting Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Condition: High Risk Smoldering Multiple Myeloma
Intervention: Drug: Ibrutinib
15 Recruiting Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Conditions: Metastatic Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: Ibrutinib;   Drug: Nivolumab
16 Recruiting Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: obinutuzumab
17 Recruiting Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Carcinoid Tumors;   Pancreatic NET
Intervention: Drug: Ibrutinib
18 Recruiting Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Ibrutinib
19 Recruiting Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment;   Biological: Trivalent Influenza Vaccine
20 Recruiting A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.